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The incidence of infection after primary total knee arthroplasty 
(TKA) has been reported to be 1% with an increase to 5% in 
patients with revision TKA1,2). For many years, the gold standard 
for treatment of chronic periprosthetic joint infection (PJI) has 
been two-stage revision. Static cement antibiotic spacers are well 
known to be an effective treatment for infection in TKA3,4). Static 
cement spacers provide local antibiotic therapy while maintain-
ing soft-tissue tension until the second stage procedure. With the 
use of static spacers, the leg is braced with minimal motion. This 
may lead to stiffness of the knee and problems such as bone loss, 
pain, scarring, and instability5,6).
To overcome these problems, articulating spacers have been de-
veloped. Articulating spacers have the advantage that they allow 
weight bearing and maintain joint movement, thereby improving 
patient’s satisfaction, reducing bone loss, facilitating the second-
stage procedure, and resulting in a greater range of motion (ROM) 
in the end7). Several studies have shown articulating spacers have 
the same reinfection rates as static spacers while, to some extent, 
preserving the function of the knee in between stages8,9). 
A number of methods using articulating spacers have been de-
scribed. Two types of cement-on-cement articulating spacer have 
been presented: either those that can be made during operation 
using antibiotic-loaded cement and silicon mold components 
or prefabricated and commercially available cement spacers9,10). 
Articulating spacers can also be made reusing the original auto-
claved femoral component with a new tibial polyethylene insert 
or using a new femoral component and a new tibial polyethylene 
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insert (NFC spacer; PFC Sigma, Depuy Synthes, Warsaw, IN, 
USA). Both techniques have shown good results with regard to 
infection control and ROM11).
The aim of this paper is to report our experience with an NFC 
spacer in terms of both eradication of infection and functional 
improvement. 
Materials and Methods
From December 2010 to March 2013 (28 months), a consecu-
tive series of 32 two-stage revisions using NFC spacers were 
performed in 31 patients suspected of having a chronic infected 
TKA. We only included patients with a primary TKA who had 
not received any prior two-stage revision for PJI. In all cases, pa-
tient’s medical records and radiographs were reviewed retrospec-
tively after approval was obtained by the Danish data protection 
agency.
The diagnostic criteria for PJI are difficult and numerous defini-
tions have been proposed. In our study, patients were diagnosed 
with PJI based on clinical suspicion (pain, swelling, redness, or 
warmth), radiography, white blood cell count (WBC), and C-
reactive protein (CRP) level or microbiologic examination of 
preoperative joint fluid, although knee aspiration was not per-
formed routinely. The diagnosis was verified from microbiologic 
examination of joint tissue at the time of first-stage surgery. In 
general, a positive culture result of 2 or more than 5 intraopera-
tive cultures was considered an infection12). A PJI may be present 
although none or only one out of 5 intraoperative cultures is posi-
tive. Several other factors such as presence of purulence in the af-
fected joint, elevated synovial leukocyte count, and elevated CRP 
concentration also need to be considered in order to determine 
the presence of PJI. Retrospectively, all our cases were confirmed 
to have PJI according to the universally adopted new definition 
for PJI13) used to ensure consistency in definition in this study. 
Every patient underwent a 2-stage exchange with an NFC 
spacer. At first stage, the prosthetic components and bone ce-
ment were removed. Thorough debridement of the infected and 
devitalized tissue and bone was performed, which was followed 
by pulsating saline lavage. Five intraoperative cultures were taken 
from inflamed synovial tissue or bone-cement membrane before 
the administration of intravenous antibiotics12). NFC spacers 
were cemented with Refobacin Revision Bone Cement (Biomet, 
Valance, France). A sachet of 40 g Refobacin Revison Bone Ce-
ment contains 1 g gentamicin and 1 g clindamycin (Fig. 1). The 
cement was in a late doughy stage so it would not adhere well to 
the bone, thereby allowing removal without any major bone loss 
at the time of second stage procedure. 
According to a standard protocol, patients who were considered 
positive for PJI received a minimum of six-week antibiotic treat-
ment including two postoperative weeks of intravenous adminis-
tration and oral administration thereafter. Every patient received 
antibiotic treatment targeting the specific microorganism after 
consultation with a microbiologist. 
Patients were encouraged to mobilize with full weight bearing 
and perform ROM exercises as tolerated immediately after the 
first stage procedure with the help of a physiotherapist.
The second stage procedure in the revision TKA using the PFC 
Sigma TC3 Knee System (Depuy Synthes) was scheduled mini-
mum 2 weeks after the first stage procedure without antibiotic 
administration. There was no rise in the inflammatory blood 
markers combined with the clinical appearance of the soft tissue 
(Fig. 2). No joint aspiration was performed in between stages. 
Of the 32 cases identified, only 22 were included in the study. 
One patient was excluded due to prior two-stage surgery with 
a static cement spacer immediately before the two-stage revision 
using an NFC spacer and two patients died from unrelated medi-
cal reasons and were lost to follow-up. 
One patient with a bilateral NFC spacer had a dislocation ten-
dency in the left knee and a chronic resistant infection in the left 
Charcot foot. An above knee amputation of the left knee with 
an NFC spacer was required and thus this patient was excluded 
from the analysis.
Another 6 patients who had two-stage revisions using NFC 
spacers were excluded for the following reasons. First, they had 
negative tissue cultures in all 5 samples collected during the first 
Fig. 1. Anteroposterior (A) and lateral (B) radiographs of the knee with 
an new femoral component spacer on the first postoperative day.
A B
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stage of the surgery despite clinical signs of infection prior revi-
sion surgery such as pain, swelling and increased CRP. Second, 
they did not meet the other criteria for PJI according to new 
definition for PJI13). Therefore, they only received antibiotic treat-
ment ranging from 4–13 days postoperatively until negative tis-
sue cultures were obtained. They all had a successful second stage 
procedure within 4–12 weeks after the first stage surgery when 
soft tissue allowed the procedure. No reinfection was observed in 
these 6 cases. 
All patients were followed up with an outpatient visit at 6 weeks 
and 1 year after surgery. From almost all patients, American 
Knee Society knee score (AKSS), function score, and ROM were 
obtained prior to the first stage surgery and one year after the 
second stage surgery, which were registered in the Danish Knee 
Arthroplasty Registry. All patients were reviewed at “e-journal”, 
which is an internet-based medical journal for physicians where 
all contacts with the Danish Health Care System is stored, to 
ensure that no patient had any additional knee surgery at other 
institutions after the second stage procedure at our institution.
The result after the 2-stage revision using an NFC spacer was 
considered successful when eradication of infection was achieved 
using only one NFC spacer. 
results
The 22 cases meeting the diagnostic criteria for PJI and in-
cluded in the follow-up consisted of 12 females 10 males with an 
average age of 65.7 years (range, 49 to 82 years). All had a two-
stage revision using an NFC spacer with a mean follow-up of 37.6 
months (range, 25 to 52 months).
Cases 1–15 (Table 1) had 2 or more positive tissue cultures out 
5 samples except one patient (case 5) that had negative test results 
in all 5 tissue cultures but presented obvious purulent material 
in the knee joint at the first stage surgery along with other signs 
of PJI. All 15 cases, therefore, received our standard antibiotic 
regimen with a minimum 6-week antibiotic treatment before the 
second stage procedure. Eradication of infection was achieved 
using only one NFC spacer in all 15 cases and no reinfection was 
observed.
Cases 16–18 were primarily not considered positive for PJI 
because none or only one out of 5 intraoperative cultures was 
positive. Therefore, they only received antibiotic treatment for a 
few days postoperatively until negative tissue cultures were ob-
tained. Retrospectively, PJI was confirmed by the new definition 
for PJI13) in the patients, and, therefore, they should have received 
a standard antibiotic regimen for a minimum of six weeks before 
the second stage procedure. However, they all had a successful 
second stage procedure and no reinfection was observed in these 
3 cases. 
Cases 19–22 were positive for PJI with 2 or more positive tissue 
cultures and had a recurrence of infection after their first second 
stage procedure. Cases 19 and 20 were treated with multiple spac-
ers (more than 2) at our institution and still remained infected, 
and consequently they were referred to other institutions for fur-
ther treatment and, therefore, they were lost to follow-up. Case 
21 was infected with coagulase-negative staphylococcus and had a 
successful two-stage procedure and no reinfection was observed 
for several years. But due to urine retention, the patient had nu-
merous urological procedures and therefore became reinfected 
with Escherichia coli as a result of hematogenous dissemination. 
The patient has undergone two-stage revision for a second time 
and just recently received a new revision TKA. Case 22 became 
reinfected with the same species (coagulase-negative staphylococ-
cus) and was treated with two-stage revision for a second time 
but has shown no sign of reinfection after receiving a second re-
Fig. 2. Anteroposterior (A) and lateral (B) radiographs following the sec-
ond stage procedure in revision total knee arthroplasty.
A B
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vision TKA more than a year ago. 
The average time from primary TKA to the first stage procedure 
was 29.1 months (range, 3 to 115 months). The average value of 
CRP was 81.7 mg/L (normal reference <8 mg/L) before the first 
stage surgery and the average value of WBC was 8.8×109/L (nor-
mal reference 3, 5–8, 8×109/L) before the first stage surgery. The 
AKSS was 29.3 (range, 3 to 59), function score was 29.5 (range, 0 
to 70), and the average ROM was 82o (range, 40o to 120o) before 
the first stage surgery.
The average time from the first stage procedure to the final sec-
ond stage procedure was 12.7 weeks (range, 4 to 45 weeks). At the 
last scheduled follow-up in our outpatient clinic 1 year postop-
eratively from the second stage surgery, the AKSS had improved 
to 66 (range, 40 to 94) and the function score was 64 (range, 45 to 
80). The average ROM had improved to 104o (range, 80o to 130o). 
Successful eradication of infection was achieved in 18 (82%) 
out of the 22 cases that were positive for PJI using only one NFC 
spacer. 
discussion
Periprosthetic infection remains a devastating and challenging 
complication of TKA for both the patient and the surgeon. Two-
stage revision with an articulating spacer has shown good results 
in terms of infection control7,9), but very few studies have been 
reported on the use of an NFC spacer as an articulating spacer in 
two-stage revision of chronic PJI in TKA11,14,15). The purpose of 
the present study was to present our short-term results using an 
NFC spacer as an articulating spacer. 
Successful eradication of infection was achieved in 18 (82%) 
of 22 cases using only one NFC spacer and this is comparable to 
other studies describing the use of an NFC spacer11); however, 
none of our patients needed long-term antibiotic suppression af-
ter the second stage procedure. 
Eradication rate of 82% is comparable to that in the study by 
Park et al.3) and Fehring et al.6) where the use of static cement 
spacers in two-stage revision resulted in the eradication rate of 
85% and 88%, respectively. Although our results in terms of the 
eradication of infection seems to be no better than that in the 
knees with static spacers, early ambulation immediately after the 
first stage surgery, which is possible due to the use of an NFC 
spacer, helps patients to perform activities of daily living, thereby 
improving patient’s satisfaction and compliance. 
Studies comparing articulating spacers with static spacers report 
greater postoperative function scores and ROM in the knees with 
articulating spacers9,16). Brunnekreef et al.16) reported significantly 
greater postoperative ROM and faster recovery in the group with 
articulating spacers. Limitations of our study include the rela-
tively small study population and the lack of comparison with a 
control group. However, our study demonstrated good functional 
results of two-stage revision with an NFC spacer: ROM increased 
from 82o to 104o and function score increased from 29.5 to 64 
postoperatively. 
Previous studies have described good results with the use of 
an autoclaved femoral component as an articulating spacer17,18). 
Compared to an NFC spacer, the autoclaved original femoral 
component is cost-effective11); however, we are concerned about 
reusing an implant designed for single use only19).
At our institution, a NFC spacer costs $573 and $150, respec-
tively. Therefore, the total price for an NFC spacer is $723, which 
is less than the price of our prefabricated articulating cement 
spacer (Spacer K–with gentamicin, Tecres, Verona, Italy), which 
costs $1,055 albeit we are aware that regional differences in pric-
ing can occur. 
Another benefit of the NFC spacer is that it gives the surgeon 
the opportunity to balance the knee by adjusting the thickness of 
the polyethylene insert compared to the prefabricated articulat-
ing cement spacers that often only come in a few sizes. 
Our study demonstrated a significantly improvement in both 
AKSS and ROM in the knees with an NFC spacer. Thus, the 
present spacer model seems to be a safe device for the treatment 
of infection of the knee offering good functional results.
conclusions
Short-term results from our study provide evidence that the use 
of a NFC spacer as an articulating spacer is effective in two-stage 
revision of chronic infected TKA with regard to eradication of 
infection and functional improvement. 
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